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ABSTRACT Phospholamban (PLB) is responsible for regulating Ca2 transport by Ca2-ATPase across the sarcoplasmic
reticulum of cardiac and smooth muscle. This regulation is coupled to -adrenergic stimulation, and dysfunction has been
associated with end-stage heart failure. PLB appears to directly bind to Ca2-ATPase, thus slowing certain steps in the Ca2
transport cycle. We have determined 3D structures from co-crystals of PLB with Ca2-ATPase by cryoelectron microscopy
of tubular co-crystals at 8–10 Å resolution. Specifically, we have used wild-type PLB, a monomeric PLB mutant (L37A), and
a pentameric PLB mutant (N27A) for co-reconstitution and have compared resulting structures with three control structures
of Ca2-ATPase alone. The overall molecular shape of Ca2-ATPase was indistinguishable in the various reconstructions,
indicating that PLB did not have any global effects on Ca2-ATPase conformation. Difference maps reveal densities which
we attributed to the cytoplasmic domain of PLB, though no difference densities were seen for PLB’s transmembrane helix.
Based on these difference maps, we propose that a single PLB molecule interacts with two Ca2-ATPase molecules. Our
model suggests that PLB may resist the large domain movements associated with the catalytic cycle, thus inhibiting turnover.
INTRODUCTION
The cycle of muscle contraction/relaxation is controlled by
the release and reuptake of Ca2 from the sarcoplasmic
reticulum (SR). Ca2 reuptake is accomplished by the ATP-
dependent pump, Ca2-ATPase, which in cardiac and
smooth muscle is regulated by phospholamban (PLB;
Kirchberger et al., 1974; Tada et al., 1974). PLB interacts
with the pump and lowers its apparent affinity for Ca2
(Simmerman and Jones, 1998); this inhibition is relieved by
-adrenergic stimulation in a mechanism involving phos-
phorylation of PLB at Ser16 by protein kinase A. Under
physiological conditions (e.g., exercise), this phosphoryla-
tion is the predominant mechanism underlying increases in
the rate of cardiac relaxation and in SR Ca2 loading (Luo
et al., 1994). However, chronic Ca2-ATPase inhibition by
PLB has been linked to SR dysfunction in human and
animal heart failure (Sordahl et al., 1973; Meyer et al.,
1995; Hasenfuss, 1998; Whitmer et al., 1988; Minmami-
sawa et al., 2000).
The SR Ca2-ATPase is a member of the family of
P-type cation pumps, all of which form a phosphorylated
intermediate during the catalytic cycle. Experimental evi-
dence has long suggested that large conformational changes
couple the formation of this phosphoenzyme to transloca-
tion of ions across the membrane. Such evidence includes
changes in proteolytic cleavage, spectroscopic signals,
chemical reactivity, and cross-linking (Jorgensen and
Andersen, 1988). The structures of Ca2-ATPase from rab-
bit skeletal muscle (Zhang et al., 1998) and H-ATPase
from Neurospora (Auer et al., 1998) revealed the confor-
mational change induced by ion binding (Stokes et al.,
1999) and the disposition of the 10 transmembrane helices.
More recently, the atomic structure of the Ca2-bound (E1)
conformation of Ca2-ATPase (Toyoshima et al., 2000)
revealed the domain architecture and overall fold. The three
cytoplasmic domains are connected by flexible links and
appear to be capable of independent motion during confor-
mational changes. Comparison with the Ca2-free (E2) con-
formation from cryoelectron microscopy (Zhang et al.,
1998) indicates that these three cytoplasmic domains do in
fact undergo large-scale, coordinated movements, which are
somehow linked to the transmembrane helices involved in
transporting the two Ca2 ions.
Enzyme kinetic studies have demonstrated that PLB
slows one or more steps in the Ca2-ATPase reaction cycle.
In particular, different studies have implicated the confor-
mational change following binding of the first Ca2 ion
(E1Ca3 E1Ca; (Cantilina et al., 1993) and phosphoenzyme
decomposition (E2-P3 E2; (Sasaki et al., 1992; Antipenko
et al., 1997). Presumably, these inhibitory effects are me-
diated by direct physical interactions between Ca2-ATPase
and PLB. In fact, specific interaction sites have been iden-
tified in the cytoplasmic domains (James et al., 1989; Toyo-
fuku et al., 1993, 1994) and transmembrane domains
(Kimura et al., 1996, 1997; Asahi et al., 1999; Cornea et al.,
2000; Autry and Jones, 1997) of each protein.
Although the structure and stoichiometry of the PLB/
Ca2-ATPase inhibitory complex are uncertain, a wide va-
riety of studies suggest that there is a dynamic exchange
between PLB monomers and pentamers. Mutagenesis of the
PLB transmembrane domain indicates that monomeric PLB
is a more effective inhibitor of Ca2-ATPase than pentam-
eric PLB (Kimura et al., 1996, 1997; Asahi et al., 1999;
Cornea et al., 2000; Autry and Jones, 1997). Furthermore,
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phosphorylation of PLB, which reverses this inhibition,
produces a larger proportion of PLB pentamers (Cornea et
al., 1997). These results are consistent with a mechanism in
which monomeric PLB interacts with and inhibits Ca2-
ATPase; pentameric PLB is postulated to be inactive and
phosphorylation to influence the distribution between these
inhibitory and inactive states (Kimura et al., 1997; Stokes,
1997). However, this mechanism may be an oversimplifi-
cation, given that a heterogeneous population of oligomers
is almost always observed, and that residues interacting with
Ca2-ATPase appear to be accessible even in the pentamer.
In this report, recombinant PLB representing different
oligomeric species has been co-reconstituted with Ca2-
ATPase under conditions suitable for tubular crystallization
(Young et al., 1997, 1998). In particular, the Asn27 to Ala
(N27A) and Leu37 to Ala (L37A) mutants were chosen
based on their differing oligomeric properties. Both inhibit
Ca2-ATPase to a greater extent than wild-type (WT), but
L37A runs exclusively as a monomer and N27A runs pre-
dominantly as a pentamer in SDS gels. After co-reconstitu-
tion, we have used frozen-hydrated electron microscopy and
helical image reconstruction to solve the structures of Ca2-
ATPase reconstituted with WT PLB, L37A, or N27A. Com-
parison with previous structures of Ca2-ATPase alone
revealed extra density, which we have assigned to the cy-
toplasmic domain of PLB and used to build a tentative
structural model for the inhibitory complex.
MATERIALS AND METHODS
Reconstitution of PLB and Ca2-ATPase
Skeletal muscle SR vesicles were prepared from rabbit hind leg (Eletr and
Inesi, 1972). Ca2-ATPase was purified from these SR vesicles by Reac-
tive Red 120 affinity chromatography (Stokes and Green, 1990). Recom-
binant PLB mutants were expressed in Sf21 insect cells using the baculo-
virus system, and purified by monoclonal antibody affinity
chromatography (Reddy et al., 1995).
Reconstitution was achieved following method II of Reddy et al. (1995),
modified for the low lipid-to-protein ratios required for crystallization
(Young et al., 1997). Purified, recombinant PLB was treated with Biobeads
SM2 (Bio-Rad Laboratories, Hercules, CA) to remove the octylglucoside,
and was lyophilized. Trifluoroethanol and chloroform were added to the
lyophilized PLB, followed by the addition of an optimal mixture of egg
yolk phosphatidylcholine, phosphatidyl ethanolamine, and phosphatidic
acid (8:1:1 weight ratio) also in chloroform. The solvents were evaporated
under dry nitrogen to yield a thin film of lipid and PLB on the wall of the
tube. This thin film was lyophilized to completely remove residual solvent.
Buffer (20 mM imidazole, pH 7.0; 100 mM KCl; 3 mM NaN3) and
detergent (C12E8) were added to resuspend the lipid/PLB film, followed by
the addition of purified Ca2-ATPase yielding a weight ratio of 1 Ca2-
ATPase/1 lipid/2 detergent. The detergent was removed by the addition of
SM2 Biobeads with stirring at room temperature for 4 h (Levy et al., 1990a,
b), with the rate of detergent removal controlled by the regimen of Biobead
addition (Young et al., 1997). Finally, sucrose density gradient centrifu-
gation was used to purify the reconstituted proteoliposomes that were
subsequently used for crystallization. Ratios of Ca2-ATPase to PLB
within these proteoliposomes were determined by SDS-PAGE (Fig. 1,
Table 1). In particular, incremental amounts of purified PLB and Ca2-
ATPase were run next to the proteoliposomes on a given gel. After
Coomassie staining, gels were digitized with a Molecular Dynamics per-
sonal densitometer SI (Sunnyvale, CA) and bands were quantitated, after
background subtraction, with the associated ImageQuant analysis software.
Lanes with purified protein were used to create separate standard curves for
Ca2-ATPase and PLB, from which the amount of each protein in proteo-
liposomes was estimated. The monomeric PLB species (L37A) was recon-
stituted to yield a final molar ratio of 1 PLB/1 Ca2-ATPase, and the
pentameric PLB species (WT and N27A) were co-reconstituted to yield a
final molar ratio of 3.5–5 PLB/1 Ca2-ATPase. ATPase activity was
measured at 25°C or 37°C by a coupled enzyme assay (Warren et al.,
1974), with EGTA-buffered Ca2 concentrations of 0.15 M and 4.0 M
(Fabiato and Fabiato, 1979). Concentrations of purified Ca2-ATPase were
determined by the modified Lowry method (Lowry et al., 1951; Markwell
FIGURE 1 (A) Quantitation of Ca2-ATPase and PLB stoichiometry in reconstituted proteoliposomes used for crystallization. Co-reconstituted samples
were run on a 6–20% gradient gel; control corresponds to reconstituted, purified Ca2-ATPase; WT, N27A, and L37A correspond to samples characterized
in Tables 1 and 2. (B) Densitometer traces of the N27A (black line) and L37A (gray line) gel lanes shown in (a). (C) Standard curve generated from purified
PLBL37A run in adjacent lanes (filled circles) used for quantitation of the L37A gel lane (open square) shown in (a); the solid line represents a linear
regression to the standard data.
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et al., 1978) and the micro BCA method (Pierce, Rockford, IL). Purified
PLB concentrations were determined by the Amido black assay (Reddy et
al., 1999). Lipid was estimated by a colorimetric determination of phos-
phorous, which is based on forming a phosphomolybdate complex (Chen
et al., 1956; Chester et al., 1987).
Tubular crystallization
The proteoliposomes were collected by centrifugation, resuspended in
buffer, and centrifuged again to wash away sucrose. To this pellet was
added crystallization buffer containing 20 mM imidazole, pH 7.4; 100 mM
KCl; 5 mM MgCl2; 0.5 mM EGTA; and 0.5 mM Na3VO4 (Dux and
Martonosi, 1983). In the cases of PLBWT, PLBL37A, and ControlTG, stoi-
chiometric levels of thapsigargin (TG) were added to this solution to
promote formation of tubular crystals (Sagara et al., 1992; Young et al.,
2001). Dansylated thapsigargin (DTG) 30 M was added for ControlDTG
as previously described (Zhang et al., 1998; Young et al., 2001). The pellet
was subjected to two freeze-thaw cycles (freezing in liquid N2, thawing in
hand), was gently resuspended at 1–2 mg/ml with a micropipette, followed
by two additional freeze-thaw cycles. Reconstituted samples were incu-
bated at 15°C for 12 h, then shifted to 0°C for several days to two weeks,
whereas Control samples were kept at 0°C for the entire time. Although
crystallization occurred quickly, four to seven days were required for the
highest frequency of tubular crystals.
Electron microscopy
Frozen-hydrated specimens were prepared by diluting crystals 20-fold with
excess crystallization buffer, and then by applying 5 l to 300-mesh copper
grids that had been coated with perforated carbon films and glow-dis-
charged in air. After blotting excess solution from the carbon side of the
grids, they were immediately vitrified in an ethane slush and were stored
in liquid N2. Images of frozen-hydrated samples were obtained with a
Philips (Eindhoven, Holland) CM200 FEG electron microscope equipped
with an Oxford (Oxford, UK) CT-3500 specimen holder, which maintained
the specimen temperature at 185°C. Images were recorded on Kodak
SO163 film at 0.6–2.0 m underfocus and at 50,000 magnification, with
doses of 10–16 electrons/Å2.
Image processing
Images of straight tubes suspended over holes in the carbon film were
selected by optical diffraction and were digitized either with a PDS 1010
GM microdensitometer (Orbital Sciences Corp., Pomona, CA) at 13 m
intervals (2.534 Å pixel size) or with a Zeiss Scai (Carl Zeiss GMBH,
Oberkochen, Germany) at 14 m intervals (2.729 Å pixel size). Like other
membranous tubes, co-crystals of PLB and Ca2-ATPase have a variable
helical symmetry characterized by Bessel orders (n) of the principal (1, 0)
and (0, 1) layer lines (Fig. 2, Toyoshima and Unwin, 1990). After deter-
mining these parameters, established procedures (DeRosier and Moore,
1970; Toyoshima and Unwin, 1990) were used for determining repeat
distances, orientational parameters, twofold phase origins, and for extract-
ing and averaging layer line data. The averaged data served as references
for correcting crystal distortions (Beroukhim and Unwin, 1997). Briefly,
individual repeat lengths of a tubular crystal were divided into short
segments (1000 Å) and independent orientational parameters were de-
termined for each section. The contrast transfer function (CTF) of individ-
ual tubes was estimated using the programs of Tani et al. (1997) assuming
4.6% amplitude contrast (Toyoshima et al., 1993). The phases were cor-
rected for the CTF before averaging layer line data, and the CTF ampli-
tudes were used as weights during final data averaging and before Fourier-
Bessel transformation (Unwin, 1993).
Because data sets for each new structure included tubes with several
helical symmetries, real-space averaging was required for calculating the
final structure (Zhang et al., 1998; Yonekura and Toyoshima, 2000). For
averaging in 3D, maps were calculated for each helical symmetry and
cross-correlation was used to determine their relative magnifications and
spatial alignment. Density scale factors were determined by linear regres-
sion of densities from corresponding pixels in the 3D maps. Individual
molecules within each map were then masked, weighted according to the
number of molecules contributing to the map, and averaged in real space.
Difference analysis
Comparisons were made among six different structures, namely three
control Ca2-ATPase structures and three structures of Ca2-ATPase
co-reconstituted with three different PLB species: PLBWT, PLBL37A, and
PLBN27A. Alignment and scaling of individual maps used the same meth-
ods as real-space averaging, and the PLBN27A map was used as an align-
TABLE 1 Co-reconstitution of Ca2-ATPase and PLB
Normalized ATPase Activity
Molar Stoichiometries 4.0 M Ca2 0.15 M Ca2
Lipid* PLB† Ab‡ Ab Ab Ab
Control 90 0 1.0§ 0.93  0.04 0.34  0.03 0.34  0.03
(n  2) (n  17) (n  2)
PLBWT 130 5 (8) 0.95  0.16 0.12  0.03
(n  12) (n  12)¶
PLBN27A 130 3.5 (5) 1.04  0.36 0.08  0.04
(n  3) (n  3)¶
PLBL37A 100 1 (2) 0.81  0.11 0.89  0.04 0.05  0.02 0.46  0.13
(n  7) (n  2) (n  7)¶ (n  2)
*Lipid/protein molar ratio after purification of proteoliposomes. In all cases the initial molar ratio was 150.
†PLB/Ca2-ATPase molar ratio after purification of proteoliposomes; initial ratios are shown in parentheses.
‡Anti-PLB monoclonal antibody 2D12, which mimics the effect of PLB phosphorylation (Briggs et al., 1992; Cantilina et al., 1993; Morris et al., 1991;
Sham et al., 1991; Reddy et al., 1996).
§ATPase activities have been normalized relative to control reconstitutions performed simultaneously and assayed at 4.0 M calcium. Average control
activity at 4.0 M calcium and 25°C was 4.22 0.19 mol/min/mg (n  17). Errors correspond to SEM.
¶Statistically significant differences relative to the control with p 	0.001.
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FIGURE 2 Representative data from individual frozen-hydrated tubular co-crystals. (A) Computed diffraction from PLBL37A. (B) Image of PLBL37A
tubular co-crystal that is 700 Å in diameter. (C) Diffraction from PLBN27A. (D) Diffraction from PLBWT. The principal layer lines and a high-order layer
line are identified by their (h, k; n) indices, where h, k correspond to Miller indices and n corresponds to the helical start number (Bessel order). Equivalent
layer lines in the diffraction patterns have the same h, k indices, but differing n, owing to variability in the helical symmetry; the (2, k; 2) layer lines
correspond to 15 Å resolution, and the (3, 11; 2) layer line corresponds to 10 Å resolution.
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ment reference because it possessed the best signal-to-noise ratio as indi-
cated by twofold phase statistics (Table 2). After alignment and density
scaling, all possible combinatorial difference maps were calculated by a
simple pixel-by-pixel subtraction (Yonekura et al., 1997).
When the twofold symmetry of the PLB-containing maps was not
enforced, PLB appeared to occupy only one of the twofold-related sites.
This asymmetry in PLB occupancy was not readily apparent in the twofold
phase statistics, which are dominated by the 18-fold larger Ca2-ATPase
molecules. Nevertheless, the lack of twofold symmetry in difference maps
prompted us to consider the polarity of the helical lattice. In the case of
PLBN27A, the better signal-to-noise ratio allowed us to detect the up-down
orientation of individual tubular crystals and 14 of the 32 tubular crystals
were thus inverted relative to their initial orientation. Even this procedure
did not fully recover PLB densities because of the following possible
effects: 1) determination of tube polarity was not 100% accurate; 2) the
occupancy of PLB was 	100%; or 3) PLB sometimes bound at the
alternate site in the unit cell, producing partial occupancy at both sites and
a consequent smearing of density.
RESULTS
Functional association between PLB
and Ca2-ATPase
ATPase activity was used to assess the functional interac-
tion between PLB and Ca2-ATPase before crystallization
(Table 1). The inhibitions produced by the PLB mutants
N27A and L37A were quite high, with 80% inhibition at
0.15 M Ca2. Consistent with previous studies, this inhi-
bition was relieved either by increased Ca2 concentration
(4.0 M) or by a monoclonal antibody to PLB (2D12),
which has been previously shown to mimic the effects of
phosphorylation (Briggs et al., 1992; Cantilina et al., 1993;
Morris et al., 1991; Sham et al., 1991; Reddy et al., 1996).
Tubular crystallization
Although the effects of decavanadate and EGTA are pri-
marily responsible for crystallization of Ca2-ATPase, ad-
dition of PLB greatly increased the number of tubular
crystals. Plausible explanations for this phenomenon are
that PLB 1) stabilizes the E2 conformation of Ca2-ATPase
(Tada et al., 1980; Cantilina et al., 1993; Antipenko et al.,
1997); 2) increases vesicle aggregates from which protein
can be recruited and tubes can grow (Young et al., 1997); or
3) affects the physical properties of the membrane similar to
fusigenic peptides (Glaser et al., 1999). At a 5:1 molar ratio
(Ca2-ATPase/PLB), all PLB species produced tubular
crystals that were easily disordered as they were prepared
for cryoelectron microscopy. However, a 1:1 molar ratio of
monomeric PLBL37A produced the best-ordered tubes (Fig.
2, a and b). Lowering the ratio of pentameric PLBN27A to
3.5:1 also produced well-ordered tubes (Fig. 2 c). This
suggests that this disorder might be due to an excess PLB in
the membrane. Even though the 5:1 molar ratio used for
PLBWT produced more disorder, sufficient numbers of rea-
sonably ordered tubes were eventually obtained for 3D
reconstruction (Fig. 2 d). The anti-PLB monoclonal anti-
body, 2D12, inhibited tube formation if added at the outset,
or disrupted existing tubular crystals if added later on,
probably due to steric hindrance of crystal contacts.
3D structure of co-crystals
Three independent structures were determined for Ca2-
ATPase in association with each of the PLB constructs, and
TABLE 2 Statistics for data analysis
Control Phospholamban
Native* TG* DTG† WT N27A L37A
Oligomeric species None None None Pentamer Pentamer Monomer
Molar ratio 5:1 3.5:1 1:1
No. of crystals 16 7 23 14 32 23
Helical symmetries 3 1 3 2 2 6
Tube diameter 700 Å 600 Å 600 Å 700 Å 700 Å 700 Å
Reference symmetry 26, 7 22, 6 22, 6 27, 8 27, 9 26, 8
No. of molecules 40,298 21,108 51,744 29,146 86,197 53,594
Twofold phase statistics (°)§
40 Å 1.2 3.9 1.4 1.4 0.7 1.7
30 Å 3.0 5.5 2.2 3.6 1.7 2.9
20 Å 16.5 11.2 6.2 11.6 3.8 7.1
14 Å 31.0 35.2 18.0 30.7 12.5 22.4
10 Å 43.5 41.1 32.2 42.1 23.8 33.8
8 Å — — 41.8 — 38.8 —
Overall 21.3 24.1 20.4 20.2 11.6 15.0
Correlation coefficients for real-space alignment¶
0.92 0.91 0.93 0.91 Reference 0.95
*Previously described by Young et al. (2001).
†Previously described by Zhang et al. (1998).
§Amplitude-weighted phase residuals for twofold symmetry including 100% of the off-equatorial data for the indicated resolution ranges. Random phases
produce a phase residual of 45°.
¶Cross-correlation coefficients range from 0 (uncorrelated) to 1 (perfect correlation).
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each was compared to native Ca2-ATPase structures: Con-
trolnative (no additives), ControlTG (Young et al., 2001), and
ControlDTG (Zhang et al., 1998). Twofold phase statistics
(Table 2) indicated that the PLBN27A reconstruction ex-
tended to at least 8 Å resolution, while the PLBwt and
PLBL37A structures extended to at least 10 Å resolution.
Similarly, Controlnative and ControlTG structures extended to
10 Å, whereas ControlDTG extended to 8 Å resolution. The
structure of Ca2-ATPase itself was indistinguishable in
these six maps. In particular, the disposition of the 3 cyto-
plasmic domains and of the 10 transmembrane helices ap-
peared to be identical to previous analyses (Young et al.,
2001; Zhang et al., 1998; Stokes et al., 1999; Stokes and
Green, 2000; Toyoshima et al., 2000).
Upon closer examination of the entire unit cell, two
features were revealed that correlated with the presence of
PLB. Although somewhat weak and inconsistent with the
expected twofold symmetry of the crystals, these features
were similar irrespective of the molar ratio or the oligomeric
species of PLB. This observation led us to look for asym-
metry of individual tubes. Because PLB is 18 times smaller
than Ca2-ATPase, its asymmetry in the unit cell has a
relatively small impact on twofold phase statistics. Also,
this asymmetry implies that PLB occupies only one of two
possible positions in the unit cell, and this position must be
consistent throughout the tube to affect phase statistics:
random positioning of PLB at either of the two possible
binding sites would simply smear out its density in the final
map. Either because of the innately low signal or because of
different levels of consistency or occupancy, we could only
detect individual tube asymmetry in the highest resolution
data set (N27A). Thus, although the same densities are
observed in the other PLB data sets, they are reduced due to
averaging of unit cells with PLB in alternate positions. In an
attempt to maximize the signal-to-noise ratio, we generated
composite maps in the presence and absence of PLB by
weighted averaging of the control structures (Native, TG,
and DTG) and PLB structures (WT, L37A, and N27A) in
real space. Sections through N27A and composite PLB
maps reveal a relatively strong density not present in the
FIGURE 3 Sections through the helical reconstructions parallel to the membrane plane. (a) Composite control; (b) PLBN27A; (c) composite PLB; (d)
atomic model viewed from the same orientation. (e) The unit cell containing two molecules is shown in red with twofold axes in yellow. (f) Side view of
the atomic model with a gray bar at the level of the sections; the arrows indicate two 90° rotations required to bring this side view to the same orientation
as the left-most Ca2-ATPase molecule in the sections. The white outline in (a–-c) corresponds to the 2.75  contour from the PLBN27A difference map,
though the equivalent density at the next unit cell has not been outlined. The atomic coordinates in (d) and (f) are color-coded according to domain: A
(yellow), N (green), and P (magenta) transmembrane, stalk, and lumenal domains are white. The blue and purple surfaces in (d) correspond to difference
densities at 2.75  from PLBN27A and composite PLB maps, respectively. Also, the side chains and solvent-accessible surface of the PLB binding loop
(Lys397-Val402) are colored white in (d).
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control maps (Fig. 3). Other sections at the surface of the
membrane (not shown) reveal continuous density adjacent
to the cytoplasmic regions of Ca2-ATPase transmembrane
segments M1, M2, and M3. Surprisingly, there were no
extra densities that could be assigned to the transmembrane
domain of PLB.
Difference maps
To quantitate structural differences in the presence of PLB,
the six maps were limited to 10 Å resolution, aligned in real
space, and densities were subtracted to produce difference
maps. In pair-wise comparisons, the two highest resolution
structures, namely ControlDTG and PLBN27A, resulted in the
strongest and cleanest difference map, owing to the higher
signal-to-noise ratio and to our ability to detect the asym-
metry of individual PLBN27A tubes (Fig. 4 a). The differ-
ence map is contoured at 2.75  of the distribution of
difference densities for both positive and negative differ-
ences. When viewed in 3D, these difference densities com-
pose a column, which bridges the nose (A) and nucleotide-
binding (N) domains of neighboring Ca2-ATPase
molecules, and an arc at the membrane interface of M1, M2,
and M3. This arc appears to extend over toward the neigh-
boring Ca2-ATPase molecule, but does not actually make
contact with it. The only large negative differences are
associated with the intramolecular decavanadate site in the
cytoplasmic domain (Stokes and Green, 2000; Toyoshima
et al., 2000) and with the TG binding site at the tip of the
lumenal domain (Young et al., 2001). These negative den-
sities reflect the lack of TG in the PLBN27A tubes and a
lower occupancy of decavanadate.
In addition to PLBN27A-ControlDTG, all pair-wise combi-
natorial difference maps were generated from the structures
described in Table 2. The nine difference maps in the
presence of PLB are shown in Fig. 4 b. Difference maps
from PLBWT and PLBL37A are expected to be noisier be-
cause the asymmetry of individual tubes could not be de-
tected. Nevertheless, positive differences dominated the gal-
lery of difference maps in two locations: one in the
cytoplasmic domain (six of the nine difference maps) and
one at the surface of the membrane (three of the nine
difference maps). Both differences were present in the high-
er-resolution difference map from PLBN27A-ControlDTG.
Only one of the nine difference maps (PLBWT-ControlTG)
showed neither feature, likely due to the fact that both of
these data sets contained the smallest number of tubular
crystals, and therefore the highest level of noise.
These other structures are represented in the difference
map between the composite PLB and composite Control
structures. Small differences in scaling required that the
upper and lower portions of the maps be re-aligned inde-
pendently. The resulting map indicates that differences from
PLBWT and PLBL37A structures are consistent with those
from PLBN27A.
DISCUSSION
Interpretation of difference maps
In the current work, three different PLB constructs were
co-reconstituted with Ca2-ATPase. After demonstrating a
functional interaction, co-crystals were grown and three
separate structures for the PLB/Ca2-ATPase inhibitory
complex were determined. The structure of Ca2-ATPase
itself appears unaffected by the presence of PLB, but con-
sistent difference densities were observed adjacent to Ca2-
ATPase. We believe these difference densities are consis-
tent with a particular model for the cytoplasmic domain of
PLB and suggest a mode for binding and inhibition. How-
ever, this interpretation is not straightforward due to the
discontinuity of difference densities and their absence from
the membrane domain. Therefore, we will first discuss the
features of our difference map to justify our assignments
and modeling of PLB.
The most likely explanation for the discontinuous differ-
ence densities is a high level of noise in the difference map.
At lower thresholds these densities are continuous, but are
also accompanied by numerous other discontinuous densi-
ties spread throughout the map. Even at the relatively high
threshold in Fig. 4, various inconsistent peaks appear in the
gallery of individual difference maps (Fig. 4 b). Given this
limitation in the signal-to-noise ratio, we believe that a
comparison of the individual difference maps (Fig. 4 b)
provides a way to distinguish real difference peaks from
noise. The composite structure in Fig. 4 c does this to some
extent, but does not distinguish whether the density labeled
“IB” continues horizontally toward the blue Ca2-ATPase
molecule or upward to connect with the density labeled
“IA.” We favor the latter interpretation, because the right-
most density (labeled “?”) is only present in one individual
difference map, whereas “IA” is present in six maps. It is
possible that this “?” density represents an alternative loca-
tion for PLB domain IA, or a partially occupied site for a
second PLB molecule within the unit cell; however, the fact
that this “?” density is not in physical contact with the blue
Ca2-ATPase molecule means that these alternatives prob-
ably do not represent the physiological binding mode for
PLB. In the transmembrane domain no plausible densities
are seen at all, leading us to conclude that the transmem-
brane helix of PLB is disordered in our crystals.
Previous models for PLB
Two basic alternatives have previously been proposed for
the structure of PLB. Both agree that the N-terminal domain
IA (residues 1–16) and the transmembrane domain II (res-
idues 33–52) are -helical. The remaining domain IB (res-
idues 17–32) has been alternately described as an -helix
(Arkin et al., 1995; Pollesello et al., 1999; Lamberth et al.,
2000) or as a relatively unstructured loop (Tatulian et al.,
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1995; Simmerman et al., 1989; Vorherr et al., 1993; Terzi et
al., 1992; Mortishire-Smith et al., 1995). This discrepancy
may be a result of solvent conditions, given that the FTIR
and CD studies supporting the loop used physiological
buffers, whereas the NMR studies revealing a helix used
either high concentrations of trifluoroethanol or a mixture of
chloroform/methanol.
Interaction of these domains with Ca2-ATPase has been
characterized by mutagenesis and, in one case, by chemical
cross-linking. One of the most important interactions ap-
pears to be between the N-terminus of PLB and the Ca2-
ATPase loop Lys397-Val402 (Toyofuku et al., 1993, 1994;
Kimura et al., 1998a). In particular, mutagenesis of either
PLB domain IA or this Ca2-ATPase loop abolishes the
FIGURE 4 Difference maps overlaid on two Ca2-ATPase molecules from the crystal lattice. (a) Difference densities from PLBN27A-ControlDTG are
rendered at 2.75 ; positive differences are purple and negative differences are green. (b) The nine individual difference maps among the three control
reconstructions (Native, DTG, and TG) and the three PLB reconstructions (WT, L37A, and N27A), showing positive differences at 2.75 . (c) Difference
densities from composite PLB-composite Control structures at 2.75 ; labels indicate our assignments to PLB cytoplasmic domains and M1, M2, and M3
transmembrane helices of Ca2-ATPase. (d) Model for a PLB monomer interacting with two Ca2-ATPase molecules. PLB domain IA (residues 1–16)
is helical and links the A and N domains of neighboring Ca2-ATPase molecules. PLB domain IB (residues 17–32) is unstructured and extends 58 Å
to make contact with the interfacial regions of M1-M3. The solvent-accessible surfaces of PLB’s Lys3 and Ser16 are yellow, whereas those of
Ca2-ATPase’s Lys397-Val402 are white; the C position of Asn27 is colored blue. Orientations of the pink and blue Ca2-ATPase molecules are shown
in the upper corners of (a).
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inhibitory capacity of PLB, and also the ability to coimmu-
noprecipitate Ca2-ATPase with an anti-PLB antibody
(Asahi et al., 2000). These studies are consistent with cross-
linking of the Ca2-ATPase loop to Lys3 of PLB in a
Ca2-dependent manner (James et al., 1989). Interaction of
domain IB with Ca2-ATPase is supported by the enhanced
inhibitory capacity of the N27A and N30A mutants, which
unlike the mutations in membrane domain II do not affect
the oligomeric state of PLB (Kimura et al., 1998b).
Our model for PLB
Using these interaction sites as constraints, we have built a
model for the cytoplasmic domain of PLB based on our
difference map. In particular, the difference density labeled
IA forms a cylinder 10 Å in diameter and 25 Å long, and
is thus compatible with the N-terminal helix of PLB (do-
main IA). Furthermore, after placing the N-terminal helix
into this density, the Lys397-Val402 loop on Ca2-ATPase
lies 9 Å from Lys3 on PLB, which is well within cross-
linking distance, especially considering that the correspond-
ing domain of Ca2-ATPase (N domain) is able to move up
to 50 Å (Toyoshima et al., 2000). The domain IA density
dwindles somewhere between Thr17 and Pro21, which is
consistent both with the NMR structures (Mortishire-Smith
et al., 1995; Arkin et al., 1995; Pollesello et al., 1999;
Lamberth et al., 2000) and with predictions of secondary
structure (Tatulian et al., 1995; Simmerman et al., 1989;
Vorherr et al., 1993; Terzi et al., 1992). When modeled as
an extended chain, domain IB is long enough to run through
the correspondingly labeled difference density, thus placing
Asn27 of PLB next to the cytoplasmic extension of M1 and
M3 of Ca2-ATPase. The lack of twofold symmetry in our
difference maps suggests a stoichiometry of only one PLB
to two Ca2-ATPase molecules.
According to the most recent NMR structure (Lamberth
et al., 2000), PLB might be modeled as a single, long
-helix with flexibility between Thr17 and Met20. This helix
would be just long enough to reach from a transmembrane
position adjoining M6 to the Lys397-Val402 loop. This alter-
native model is consistent with mutagenesis (Asahi et al.,
1999) and co-immunoprecipitation (Asahi et al., 2000) stud-
ies supporting an interaction between PLB domain II and
Ca2-ATPase M6. However, we have observed no differ-
ence densities that are consistent with this alternative, either
next to the cytoplasmic domain or within the membrane.
Instead, our model suggests that PLB domain II may enter
the membrane near M3. Unlike the unhindered region ad-
jacent to M6, there is a crystal contact at the lumenal side of
M3, which could explain the disordering of the PLB trans-
membrane domain in our co-crystals. This hypothesis re-
quires that M6 mutations exert an indirect influence over
PLB binding. Indeed, three of five sensitive M6 residues are
buried in the atomic structure, supporting the relevance of
indirect effects regardless of where PLB binds.
Functional implications of our model
PLB appears to bind preferentially to the E2 conformation
of Ca2-ATPase (James et al., 1989; Asahi et al., 2000) and
kinetic studies have specifically attributed PLB inhibition to
a slowing either of the Ca2-induced transition from E2 to
E1 (Cantilina et al., 1993) or of E2-P hydrolysis (Sasaki et
al., 1992; Antipenko et al., 1997). The catalytic cycle of
Ca2-ATPase uses dramatic domain motions that have been
recently characterized by comparing the x-ray crystal struc-
ture of the E1  Ca2 conformation (Toyoshima et al., 2000)
with the EM structure, which appears to represent either the
E2 (Stokes and Lacapere, 1994) or the E2-P conformation
(Danko et al., 2001). The most dramatic movement involves
a 90° rotation of the A domain, though the P domain also
rotates by 45° and the N domain is translated by as much as
50 Å (Toyoshima et al., 2000; Rice, Xu, and Stokes, un-
published results). According to our model, PLB links the A
and N domains of adjacent Ca2-ATPase molecules and
could therefore inhibit Ca2-ATPase by resisting these do-
main motions. Depending on the particular Ca2-ATPase
conformation stabilized by PLB (E2 or E2-P), binding could
inhibit either E2-P hydrolysis, the Ca2-induced E2 to E1
transition, or perhaps both.
Inhibition by PLB is relieved either by phosphorylation
of Ser16 or by elevated Ca2 concentrations. In our model,
Ser16 faces the A-domain of Ca2-ATPase at the end of
domain IA (Fig. 4 d) and several studies indicate that
phosphorylation causes partial unwinding of the N-terminal
helix (Tatulian et al., 1995; Simmerman et al., 1989; Terzi
et al., 1992; Mortishire-Smith et al., 1995). Such unwinding
could destabilize this intermolecular interaction and thus
allow the A domain to undergo the necessary movements
for catalysis. If PLB binding to adjacent molecules required
that they both be in the same state (e.g., E2), then an
increased rate of Ca2-ATPase turnover would reduce the
probability of simultaneously finding these molecules in
this state. Thus, PLB binding would be sensitive to the
kinetics of Ca2-ATPase, which could account for the ob-
served Ca2 dependence of PLB inhibition.
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